Skip to content

Cerus CERS Additional Paid-In Capital

Additional Paid-In Capital at other companies

Haemonetics logo
HaemoneticsHAE
$554.14M+5.9%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$1.12B+7.8%

Other financials

Income statement

See full
Revenue$53.7M+24.1%
Operating income-$354.0K+94.0%
Net income-$1.6M+78.7%
EPS (diluted)-$0.01+75.0%

Balance sheet

See full
Cash & equivalents$27.9M+43.0%
Total debt$45.0M-43.3%
Total equity$67.6M+21.7%
Total assets$222.9M+7.8%

Cash flow

See full
Operating cash flow-$3.0M-261%
CapEx$233.0K+108%
Free cash flow-$3.3M-243%

Valuation

See full
Market cap$573.06M+124%
Enterprise value$590.17M+86.7%
P/S2.9×-1.0×

Profitability

See full
Gross margin64%
Operating margin-6.2%-2.1pp
Net margin-9.8%-2.8pp
FCF margin3.5%+1.9pp

Returns & leverage

See full
Return on equity-15.5%-5.6pp
Debt / equity0.7×-0.8×
Current ratio1.6×-0.7×

Where this comes from

Reported directly by Cerus in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Cerus’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cerus's additional paid-in capital?
Cerus (CERS) reported additional paid-in capital of $1.15B in Q1 2026.
How has Cerus's additional paid-in capital changed year-over-year?
Cerus's additional paid-in capital increased by 1.9% year-over-year, from $1.13B to $1.15B.
What is the long-term trend for Cerus's additional paid-in capital?
Over 5 years (2020 to 2025), Cerus's additional paid-in capital has grown at a 2.5% compound annual growth rate (CAGR), from $1.01B to $1.15B.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.